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The triple-base-pair 16S rDNA mutation AGA926-9283TTC mediates high-level tetracycline resistance in
Helicobacter pylori. In contrast, single- and double-base-pair mutations mediated only low-level tetracycline
resistance and decreased growth rates in the presence of tetracycline, explaining the preference for the TTC
mutation in tetracycline-resistant H. pylori isolates.
Tetracycline is a cheap and effective antibiotic for the treat-
ment of Helicobacter pylori infections (7, 8), but in the past few
years the incidence of tetracycline resistance has significantly
increased (1, 5, 6, 9, 13). The only known mechanism mediat-
ing tetracycline resistance in H. pylori involves mutations at
positions 926 to 928 in both the 16S rRNA genes (2, 4, 12). H.
pylori strains with high-level tetracycline resistance (Tetr) car-
ried the triple-base-pair mutation AGA926-9283TTC in both
copies of the 16S rRNA genes (4, 12), whereas strains with
low-level Tetr contained only single- and double-base-pair mu-
tations in the exact same region (2). As the different mutations
were present in unrelated strains, it is still unclear whether
high-level tetracycline resistance requires the AGA926-9283
TTC mutation or whether single- or double-base-pair muta-
tions at these positions may suffice for high-level tetracycline
resistance. Therefore, we have created all possible combina-
tions of single, double, and triple mutations at the 16S rRNA
gene positions 926 to 928 in H. pylori strain 26695 and have
determined the effects of the mutations on levels of tetracy-
cline resistance, stability, and growth rate.
Site-directed mutagenesis at positions 926 to 928 was carried
out by using a three-step PCR approach (3, 10) with primers
listed in Table 1, followed by natural transformation to H.
pylori reference strain 26695 (4). Tetr H. pylori colonies were
selected on plates containing tetracycline (1 g/ml). For each
possible base pair mutation or combination thereof, eight Tetr
transformants from at least two independent transformation
experiments were selected. Both alleles of the 16S rRNA genes
were amplified by PCR (4) to confirm the presence of the
desired base pair mutations. With the exception of the AGC
mutants, all mutants contained the desired mutations in both
alleles of the 16S rRNA genes. All AGC mutants were het-
erozygous and contained the AGC mutation in the rrnA gene
and a TTC mutation in the rrnB gene.
The effects of the 16S rRNA mutations on both the stability
and the level of tetracycline resistance were determined by
subculturing two mutants of each type for 20 passages on
Columbia agar plates supplemented with 7% lysed horse blood
(BioTrading, Mijdrecht, The Netherlands) in either the pres-
ence or absence of tetracycline (1 g/ml). After each five
rounds of subculturing, the MIC of tetracycline was deter-
mined by using E-test (AB Biodisk, Solna, Sweden) (4). In
addition, for all mutants at time point zero (t0) and after
passage 20 (t20), the 16S rRNA genes were sequenced. The
stability of the various types of mutations and their effects on
the levels of resistance are summarized in Table 2.
At t0, the single- and double-base-pair mutations did not
result in tetracycline resistance with levels of clinical relevance,
as the MIC of tetracycline was below 4 g/ml. With the excep-
tion of those for the AGC mutants, the MICs of tetracycline at
t20 were similar to those at t0 (Table 2). The MIC of tetracy-
cline for the AGC mutants increased from 1.5 to 6.0 g/ml.
Subsequent analysis of the 16S rRNA gene sequences of all
mutants at t0 and t20 revealed that the TGA and AGC muta-
tions were unstable. Already during the two subculturing steps
needed for propagation of the colonies to obtain sufficient
material for storage at 80°C, the sequences of both 16S
rRNA genes of the TGA mutants had changed to TGC, and
while stable during the initial propagation steps, after 20
rounds of subculturing both AGC mutants contained a TTC
sequence at positions 926 to 928 within both 16S rRNA genes
instead of only in the rrnB gene. Apart from these TGC and
AGC mutations, all other mutations were stable as the com-
plete 16S rRNA gene sequences did not reveal any other se-
quence changes except for the desired mutations.
To determine whether the 16S rRNA mutations affected the
growth rates of the mutants in the presence or absence of
tetracycline, all mutants from t0 were cultured in duplicate in
brucella broth supplemented with 3% newborn calf serum
(Life Technologies Ltd., Auckland, New Zealand). One cul-
ture of each mutant was supplemented with tetracycline (1
g/ml), whereas the other culture was kept unsupplemented.
Growth was monitored by measuring the optical density at 600
nm each 24 h for a period of 72 h. In the absence of tetracy-
cline, the growth of the mutants did not differ from that of the
H. pylori wild-type strain 26695 (Table 2). However, in the
presence of tetracycline the growth of the wild-type strain and
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the mutants with single- and double-base-pair mutations was
clearly reduced compared to that of the TTC mutant. The
reduction was most pronounced in the wild-type strain and the
AGC, ATA, and TGC mutants (Table 2).
From this study it is apparent that for high-level tetracycline
resistance, H. pylori requires the triple-base-pair mutation
AGA926-9283TTC in both copies of the 16S rRNA genes. Such
high-level tetracycline resistance is most likely generated by a
stepwise process that is driven by selection that depends on
both the duration of exposure to and the dose of tetracycline.
For this reason, it was not surprising that the previously de-
scribed H. pylori strains with low-level Tetr contained only
single- or double-base-pair mutations in the exact same region
as the TTC mutation (2). In this report (2) it was also sug-
TABLE 1. Primers used in this study
Primer Sequence (5–3)a Position relative to 16SrRNA geneb
16S rRNA
mutationc
Sequencing, cloning, and PCR
Hp16S-F1 CTGACGCTGATTGCGCGAAA 711–730, forward NA
Hp16S-F2 CCTGCTGGAACATTACTGAC 696–715, forward NA
Hp16S-F3 TTTATGGAGAGTTTGATCCT 1–20, forward NA
Hp16S-F4 TAGTTGTTGGAGGGCTTAGT 789–808, forward NA
Hp16S-R1 TCGTTGCGGGACTTAACCCA 1071–1052, reverse NA
Hp16S-R2 TGGCTCCACTTCGCAGTATT 1245–1226, reverse NA
Hp16S-R3 AGGAGGTGATCCAACCGCA 1499–1480, reverse NA
Hp16S-rrnA CCCAAATCCTTGAGCGTTTA 1840–1821, reversed NA
Hp16S-rrnB CGCATTCATAATCAGCTCAG 1826–1807, reversee NA
Mutagenesis
Hp16S-mutF1 TAATTCGATGATACACGAAG 918–937, forward TGA
Hp16S-mutF2 TAATTCGAATATACACGAAG 918–937, forward ATA
Hp16S-mutF3 TAATTCGAAGCTACACGAAG 918–937, forward AGC
Hp16S-mutF4 TAATTCGATTATACACGAAG 918–937, forward TTA
Hp16S-mutF5 TAATTCGATGCTACACGAAG 918–937, forward TGC
Hp16S-mutF6 TAATTCGAATCTACACGAAG 918–937, forward ATC
Hp16S-mutF7 TAATTCGATTCTACACGAAG 918–937, forward TTC
Hp16S-mutR1 CTTCGTGTATCATCGAATTA 937–918, reverse TGA
Hp16S-mutR2 CTTCGTGTATATTCGAATTA 937–918, reverse ATA
Hp16S-mutR3 CTTCGTGTAGCTTCGAATTA 937–918, reverse AGC
Hp16S-mutR4 CTTCGTGTATAATCGAATTA 937–918, reverse TTA
Hp16S-mutR5 CTTCGTGTAGCATCGAATTA 937–918, reverse TGC
Hp16S-mutR6 CTTCGTGTAGATTCGAATTA 937–918, reverse ATC
Hp16S-mutR7 CTTCGTGTAGAATCGAATTA 937–918, reverse TTC
a Primers used for amplification were based on the published genome sequence of H. pylori strain 26695 (11). The substituted residues are underlined.
b Positions of oligonucleotides are given relative to the start point of the rrnA gene of H. pylori strain 26695 (11).
c 16S rRNA mutations at positions 926 to 928 (numbering according to sequence of the rrnA gene of H. pylori strain 26695) (11). The substituted residues are
underlined. NA, not applicable.
d The rrnA-specific oligonucleotide is located outside the 16S rRNA gene at positions 1207242 to 1207261 of the H. pylori 26695 genome sequence (4, 11).
e The rrnB-specific oligonucleotide is located outside the 16S rRNA gene at positions 1510809 to 1510828 of the H. pylori 26695 genome sequence (4, 11).
TABLE 2. Characterization of mutants construction by using site-directed mutagenesis
Strain or mutanta




On TET-free medium On TET (1g/ml) On TET-free mediumd On TET (1 g/ml)e
Wild-type strain 26695 0.19 0.19 0.19  No growth
TGAf ND ND ND ND ND
ATA 1.5 1.5 2.0  
AGCg 1.5 6.0 6.0  
TTA 1.5 2.0 2.0  
TGC 1.0 1.5 2.0  
ATC 2.0 2.0 3.0  
TTC 6.0 6.0 8.0  
a The substituted residues are underlined.
b MIC were determined by using E-test for two independent mutants. MIC shown are means of results from four to six independent experiments. TET, tetracycline;
ND, not determined.
c At t0 all mutants were already subcultured twice in order to obtain sufficient bacteria for storage at 80°C.
d Growth rates of the isogenic mutants relative to the growth rate of the wild-type strain 26695 (100%). , 95 to 100%; , 70 to 95%; , 50 to 70%.
e Growth rates of the isogenic mutants containing single- and double-base-pair mutations relative to the growth rate of the isogenic mutants containing the
triple-base-pair mutation TTC (100%). , 95 to 100%; , 70 to 95%; , 50 to 70%.
f The TGA sequence had already changed into the TGC sequence during subculturing before storage.
g Each of the tested mutants contained an AGC mutation in the rrnA gene and a TTC mutation in the rrnB gene.
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gested that mutant H. pylori strains with even a small increase
in tetracycline resistance have an advantage whenever inhibi-
tory concentrations of tetracycline are encountered. However,
it could not be excluded that the observed differences were due
to strain differences or secondary mutations. The data pre-
sented here have been obtained from mutants with identical
genetic backgrounds, thus excluding the effect of strain differ-
ences. Taken together, the data indicate that the preference in
H. pylori for particular 16S rRNA gene mutations mediating
tetracycline resistance results not only from the differences in
MICs but also from the differences in growth rates in the
presence of tetracycline and from the stability of the mutations.
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